Pretreatment with KF41399 improved thrombocytopenia caused by ACNU
| Protocol . | Day 0 . | Day 4 . | Day 7 . | Day 9 . | Day 11 . | Day 14 . | Day 17 . | Day 21 . |
|---|---|---|---|---|---|---|---|---|
| A | 95.0 ± 3.2 | 86.1 ± 8.6 | 92.4 ± 7.8 | 92.0 ± 9.4 | 89.4 ± 2.4 | 94.2 ± 4.6 | 95.1 ± 7.1 | 85.4 ± 3.0 |
| D | 102.7 ± 13.0 | 93.6 ± 3.6 | 107.0* ± 11.9 | 96.8* ± 10.2 | 57.2* ± 5.3 | 54.1* ± 10.1 | 66.0 ± 8.3 | 83.6 ± 13.8 |
| E | 101.1 ± 3.0 | 88.9 ± 11.4 | 84.0 ± 8.0 | 30.6 ± 10.5 | 15.2 ± 10.6 | 58.4 ± 34.3 | 95.9 ± 46.0 | 90.6 ± 46.7 |
| F | 97.4 ± 8.0 | 89.8 ± 5.0 | 75.7 ± 6.6 | 39.2 ± 2.6 | 12.2 ± 2.7 | 22.0 ± 6.4 | 42.6 ± 11.8 | 50.6 ± 11.7 |
| I | 100.9 ± 11.1 | 88.8 ± 6.1 | 78.8* ± 2.0 | 28.0* ± 8.5 | 9.0* ± 3.0 | 17.5* ± 13.7 | 35.9 ± 26.2 | 59.0 ± 31.5 |
| Protocol . | Day 0 . | Day 4 . | Day 7 . | Day 9 . | Day 11 . | Day 14 . | Day 17 . | Day 21 . |
|---|---|---|---|---|---|---|---|---|
| A | 95.0 ± 3.2 | 86.1 ± 8.6 | 92.4 ± 7.8 | 92.0 ± 9.4 | 89.4 ± 2.4 | 94.2 ± 4.6 | 95.1 ± 7.1 | 85.4 ± 3.0 |
| D | 102.7 ± 13.0 | 93.6 ± 3.6 | 107.0* ± 11.9 | 96.8* ± 10.2 | 57.2* ± 5.3 | 54.1* ± 10.1 | 66.0 ± 8.3 | 83.6 ± 13.8 |
| E | 101.1 ± 3.0 | 88.9 ± 11.4 | 84.0 ± 8.0 | 30.6 ± 10.5 | 15.2 ± 10.6 | 58.4 ± 34.3 | 95.9 ± 46.0 | 90.6 ± 46.7 |
| F | 97.4 ± 8.0 | 89.8 ± 5.0 | 75.7 ± 6.6 | 39.2 ± 2.6 | 12.2 ± 2.7 | 22.0 ± 6.4 | 42.6 ± 11.8 | 50.6 ± 11.7 |
| I | 100.9 ± 11.1 | 88.8 ± 6.1 | 78.8* ± 2.0 | 28.0* ± 8.5 | 9.0* ± 3.0 | 17.5* ± 13.7 | 35.9 ± 26.2 | 59.0 ± 31.5 |
Values are ×104/μL.
KF41399 or ACNU, or both, was administered according to the schedule of protocols A, D, E, F, and I in Table 1, and peripheral platelet counts were analyzed as described in “Materials and methods.” Results are expressed as mean ± SD.
N = 5 in each group.
P < .05.